Science

Revolutionizing delivery
across the blood-brain barrier.

 

Our Platform: TRACER

Reaching CNS targets once thought unreachable.

Voyager’s TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform is a broadly applicable, RNA-based screening platform that enables rapid discovery of AAV capsids with robust penetration of the blood-brain barrier and enhanced central nervous system (CNS) tropism in multiple species, including non-human primates (NHPs).

Non-Viral Approaches

Multiple modalities to treat neurological diseases.

The Voyager team has expertise in the discovery and development of monoclonal antibodies as well as in receptor-mediated non-viral delivery to the central nervous system.

“I love how we all get to collaborate, even though we are on different teams.”

Gretchen Rivera, Research Associate II, Vector Genome

Recent Publications & Presentations

ADPD 2024:
Intravenous administration of BBB-penetrant AAV containing primary artificial microRNA targeting tau reduces tau broadly and robustly in hTau mouse brain

Pharmacokinetics and tolerability of VY-TAU01, an anti-tau antibody for the treatment of Alzheimer’s disease, in P301S mouse and nonhuman primate

In Vivo Gene Therapy and Genome Editing Summit 2023:
Iterative Evolution of Cross-Species BBB-Penetrant Capsids​

BioProcessing Summit 2023:
Rapid HEK Platform Scale Up to 200 L Using kLa Modeling

 

Our Pipeline

Transforming breakthrough science into medicines.

Partnerships

Our allies in realizing the potential of neuro-genetic medicines